Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV) from its SEC filings: 2025 revenue $8.3 million (-72% vs the year before), net margin -3629%, free cash flow -$758.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $8.3 million |
| Revenue growth | -72% |
| Net income | -$299.8 million |
| Net margin | -3629.2% |
| Free cash flow | -$758.6 million |
| Diluted EPS | $-0.54 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -34% |
| Cash | $1.2 billion |
| Long-term debt | $210.0 million |
| Share count, 1 year | +6% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.